About Glyx Therapeutics

Glyx Therapeutics is a biotechnology company dedicated to developing first-in-class, oral, brain-penetrant therapies to transform the treatment of tauopathies, including Alzheimer’s disease, Progressive Supranuclear Palsy (PSP), and Pick’s disease.

Our lead candidate, Mal16diS, targets the root cause of neurodegeneration—the pathological aggregation of tau protein—offering a disease-modifying approach where none currently exist.

Driven by scientific excellence and sustainable innovation, we combine green chemistry with cutting-edge research to create accessible, eco-friendly solutions. Our mission is to restore hope and independence to patients and families affected by neurodegenerative diseases, while advancing the frontier of precision neurology.